美股异动 | 维罗纳制药盘前涨超 80% Ensifentrine 成功达到试验主要和次要终点

YiCai
2022.12.20 09:09
格隆汇 12 月 20 日 | 维罗纳制药 (VRNA.US) 盘前涨超 80%，报 24.74 美元。该公司今天宣布 ENHANCE-1 3 期试验的积极结果，该试验评估了雾化 Ensifentrine 对慢性阻塞性肺疾病的维持治疗。Ensifentrine 成功地达到了其主要和次要终点，显示出肺功能、症状和生活质量方面的明显改善。此外，Ensifentrine 大大降低了慢性阻塞性肺疾病恶化的速度和风险。Ensifen
Source: YiCai The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.